Welcome to our dedicated page for Lobe Sciences news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences stock.
Lobe Sciences Ltd. (OTCQB: LOBEF) generates news primarily as a clinical-stage biopharmaceutical company advancing therapies for diseases with significant unmet medical needs. The company’s disclosures highlight programs in rare neurological and hematological conditions, including chronic cluster headache and sickle cell disease, advanced through its subsidiaries Cynaptec Pharmaceuticals, Inc. and Altemia, Inc.
News updates for Lobe Sciences often cover developments in its lead CNS therapeutic candidate L-130 (also referred to as Conjugated Psilocin™ or psilocin mucate), which is being developed by majority-owned Cynaptec for chronic cluster headache and potential additional CNS indications under strategic review. Announcements have described completion of a Phase 1a study in healthy volunteers, ongoing work aligned with U.S. FDA Pre-IND guidance, and financing transactions at the subsidiary level intended to support further development.
Investors and followers of LOBEF can also expect coverage of Altemia, Inc.’s work on S-100, an early-stage therapeutic candidate for sickle cell disease, and a proprietary medical food in early-stage distribution aimed at addressing nutritional deficiencies commonly observed in patients with sickle cell disease. Company news has discussed how Lobe prioritizes S-100 within its sickle cell program and maintains limited commercialization efforts while assessing reimbursement pathways.
Lobe Sciences’ news flow additionally includes corporate and capital markets updates, such as private placements, debt settlements through equity issuance, leadership transition, Board renewal, and the appointment of new directors with experience in corporate governance, securities law, and international pharmaceutical business development. The company also reports on participation in industry conferences and patient-focused events related to cluster headache and other underserved conditions. Readers interested in LOBEF can use this news page to follow the company’s clinical progress, financing activities, governance developments, and strategic initiatives as disclosed in its official releases.
Lobe Sciences (OTCQB:LOBEF), a clinical stage biopharmaceutical company, has appointed Marco Mastrodonato to its Board of Directors. Mastrodonato brings significant pharmaceutical and biotechnology industry experience, having previously co-founded Sinclair Pharma plc and served as Executive Director of the London Stock Exchange-listed company.
Mastrodonato's extensive background includes founding Metrodora Therapeutics and serving as CEO of BMG Pharma, where he leads development of hyaluronic acid-based technologies. Dr. Fred Sancilio, Lobe Sciences' Chairman and CEO, highlighted their 30-year professional relationship and Mastrodonato's proven success across European and Middle Eastern markets.
Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company specializing in rare and underserved diseases, has completed its previously announced non-brokered private placement. The company issued 8,535,625 common shares at $0.04 per share, raising total gross proceeds of $341,425 CAD.
The securities issued will be subject to a four-month and one-day statutory hold period. The offering, initially announced on July 29th, was not registered under the U.S. Securities Act and cannot be offered or sold in the United States without registration or an applicable exemption.
Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company focused on rare and underserved diseases, has announced a non-brokered private placement offering. The company plans to issue up to 8,535,625 common shares at $0.04 CAD per share, aiming to raise gross proceeds of up to $341,425 CAD.
The funds will be utilized for general corporate purposes and working capital needs. The issued securities will be subject to a four-month and one-day holding period and are not registered under the U.S. Securities Act.
Lobe Sciences (OTCQB:LOBEF), a biopharmaceutical company developing therapeutics for rare and underserved diseases, has engaged ArcStone Securities and Investments Corp. for capital markets advisory services. The partnership aims to enhance Lobe's market visibility and institutional investor engagement across North American markets.
Under the agreement, ArcStone will provide comprehensive advisory services including capital markets planning and strategic positioning. The collaboration is effective immediately, with ArcStone's expertise expected to support Lobe's development programs and strengthen its presence in both Canadian and U.S. financial markets.
Lobe Sciences Ltd. (OTCQB:LOBEF), a biopharmaceutical company, has announced a debt settlement through a share issuance. The company has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for previous legal services by issuing 546,206 common shares at a deemed price of CAD$0.02123 per share.
The shares were issued on May 13, 2025, and are subject to regulatory hold periods under Canadian securities laws.
Lobe Sciences (OTCQB:LOBEF) has announced the validation of its European Unitary Patent EP4117446 across 17 EU member states for its DHA-based composition targeting Sickle Cell Disease (SCD).
The patent specifically covers Altemia®, a physician-supervised medical food formula designed to address long-chain fatty acid deficiencies in SCD patients. The formulation combines DHA and natural emulsifiers to improve bioavailability and restore red blood cell membrane integrity.
This validation represents a significant expansion of Lobe's intellectual property protection in key European markets, strengthening the company's position for broader commercialization of Altemia®.
Lobe Sciences (LOBEF) has announced a significant private placement through its newly created subsidiary Cynaptec Pharmaceuticals. The deal includes an initial US$6 million investment and an additional US$20 million option, potentially totaling US$26 million.
Cynaptec will own and develop the company's Conjugated Psilocin™ technology, receiving worldwide patents and related IP from Lobe Sciences in exchange for 6,399,900 shares of Common Stock. The initial placement involves issuing 3,600,000 Series A-1 Preferred Stock shares at US$1.66 per share.
The funding will support preclinical research, Phase 1, and Phase 2a clinical studies, with the optional US$20 million designated for Phase 3 clinical trials in chronic cluster headache treatment. Post-investment, Lobe Sciences retains 64% ownership of Cynaptec, which could decrease to 32% if the investor fully exercises their option within 120 days following completion of specific clinical milestones.
Lobe Sciences (LOBEF) has provided a comprehensive corporate update detailing several key transactions and operational developments. The company issued multiple convertible notes throughout 2024, including C$678,450 in March, C$1,462,716 in May, and US$250,000 in December, all bearing 10% annual interest.
The company settled various debts through share issuances, including 16.4M shares to Clearway Global, 10.8M shares to former directors and officers, and implemented a director compensation agreement involving 7M shares per director. Additionally, 3.5M restricted share units were issued to a subsidiary officer.
On the operational front, Lobe Sciences highlighted progress with Conjugated Psilocin™, securing two US patents and filing international applications. The company published Phase 1 clinical trial results and received pre-IND feedback from the FDA, marking significant steps toward human clinical trials.